Peptides you’ll hear about
Status as of October 2026. Rules are changing, so check the date on each article and the current rule on the FDA’s website.
| Peptide | Status | What to know |
|---|---|---|
| Semaglutide (Ozempic, Wegovy, Rybelsus) | FDA-approved | Weekly injection or daily pill. The Wegovy pill was approved in December 2025. |
| Tirzepatide (Mounjaro, Zepbound) | FDA-approved | Acts on two gut-hormone receptors. Zepbound is also approved for sleep apnea in adults with obesity. |
| Liraglutide (Victoza, Saxenda) | FDA-approved | An older, once-daily GLP-1. |
| Compounded semaglutide or tirzepatide | Compounded · Rx | Sharply limited since the shortages were declared over in late 2024 and early 2025. |
| Retatrutide | Research-only | Not approved. Lilly plans to file for approval in early 2027. Anything sold online now is not the trial drug. |